Natera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types

Reuters06-04

Natera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types

Natera Inc., a leader in cell-free DNA and precision medicine, has announced that its Signatera™ MRD assay has received Medicare coverage under LCD L38779. This comprehensive coverage extends to Medicare beneficiaries with colorectal, breast, bladder, ovarian, and lung cancers, as well as for pan-cancer immunotherapy monitoring. The decision is backed by extensive validation through over 100 published clinical studies. The announcement follows Natera's recent presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where they showcased a pan-cancer study involving 392 patients. This development underscores the clinical utility and validity of the Signatera assay, providing broader access to innovative MRD testing for Medicare patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604942709) on June 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2540509560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540509560","market":"nz","top_or_hot":-1,"title":"Natera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Natera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Natera Inc., a leader in cell-free DNA and precision medicine, has announced that its Signatera™ MRD assay has received Medicare coverage under LCD L38779. This comprehensive coverage extends to Medicare beneficiaries with colorectal, breast, bladder, ovarian, and lung cancers, as well as for pan-cancer immunotherapy monitoring. The decision is backed by extensive validation through over 100 published clinical studies. The announcement follows Natera's recent presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where they showcased a pan-cancer study involving 392 patients. This development underscores the clinical utility and validity of the Signatera assay, providing broader access to innovative MRD testing for Medicare patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604942709) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-04 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Natera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Natera Inc., a leader in cell-free DNA and precision medicine, has announced that its Signatera™ MRD assay has received Medicare coverage under LCD L38779. This comprehensive coverage extends to Medicare beneficiaries with colorectal, breast, bladder, ovarian, and lung cancers, as well as for pan-cancer immunotherapy monitoring. The decision is backed by extensive validation through over 100 published clinical studies. The announcement follows Natera's recent presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where they showcased a pan-cancer study involving 392 patients. This development underscores the clinical utility and validity of the Signatera assay, providing broader access to innovative MRD testing for Medicare patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604942709) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064131342.USD","symbol_name":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL3RQ4Nx:1","article_id":"2540509560","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540509560","pubTimestamp":1749034831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Natera Inc., a leader in cell-free DNA and precision medicine, has announced that its Signatera MRD assay has received Medicare coverage under LCD L38779. This comprehensive coverage extends to Medicare beneficiaries with colorectal, breast, bladder, ovarian, and lung cancers, as well as for pan-cancer immunotherapy monitoring. The decision is backed by extensive validation through over 100 published clinical studies. The announcement follows Natera's recent presentation at the 2025 American Society of Clinical Oncology  Annual Meeting, where they showcased a pan-cancer study involving 392 patients. This development underscores the clinical utility and validity of the Signatera assay, providing broader access to innovative MRD testing for Medicare patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","NTRA":"Natera, Inc.","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC"},"translate_title":"Natera Inc.为Signatera™针对多种癌症类型的基于基因组的MRD检测获得医疗保险承保","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":0.9},"content_text":"Natera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types\n    \n\n        Natera Inc., a leader in cell-free DNA and precision medicine, has announced that its Signatera™ MRD assay has received Medicare coverage under LCD L38779. This comprehensive coverage extends to Medicare beneficiaries with colorectal, breast, bladder, ovarian, and lung cancers, as well as for pan-cancer immunotherapy monitoring. The decision is backed by extensive validation through over 100 published clinical studies. The announcement follows Natera's recent presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where they showcased a pan-cancer study involving 392 patients. This development underscores the clinical utility and validity of the Signatera assay, providing broader access to innovative MRD testing for Medicare patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604942709) on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2540509560","isCrawlerRequest":true}